Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $217.00. The ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

Fluent Ventures, with $40 million, is backing founders who are replicating proven business models in fintech, health, and ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neuroscience and neurodegenerative diseases with a market capitalization of $17.45 billion, finds itself at a ...

Shout! Studios has acquired distributor Gravitas Ventures under its strategy to build the library as it continues to acquire and distribute film and television through for its multi-platform ...

Shares of Biogen Inc. BIIB shed 3.08% to $119.19 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.23% to 5,062.25 and Dow ...

Shout! Studios has acquired Gravitas Ventures from Anthem Sports & Entertainment. Financial terms of the sale were not disclosed. Shout! Studios said that, by acquiring Gravitas Ventures ...

The acquisition gives Shout! access to Gravitas Ventures’ library of 3,300 scripted, non-scripted, and sports-related feature film, documentary, and TV titles, and it means that Shout!